Join to View Full Profile
825 Eastlake Ave ESeattle, WA 98109
Phone+1 855-557-0555
Fax+1 206-606-1025
Dr. Till is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007- University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2002 - 2005
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2002
Certifications & Licensure
WA State Medical License 2005 - 2027
PA State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2012 Aug 09
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2017 Nov 27
Roles: Principal Investigator
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Start of enrollment: 2017 Dec 05
Publications & Presentations
PubMed
- Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.Ryan C Lynch, Ryan D Cassaday, Stephen D Smith, Andrew J Cowan, Edus H Warren
British Journal of Haematology. 2025-10-01 - Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy.Sai Kit Ng, Patrick W Flaherty, Melissa Ancheta, Karyn A Tindbaek, Mandeep K Sekhon
Transplantation and Cellular Therapy. 2025-10-01 - Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia.Christina Poh, Xueyan Chen, Jenna Voutsinas, Kikkeri Naresh, Jerlin J Dizon
British Journal of Haematology. 2025-09-10
Abstracts/Posters
- Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell LymphomasBrian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...Brian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical OutcomesBrian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
- Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
